https://www.live-feeds.com/feed/fda-s-new-leadership-aims-to-overhaul-rare-disease-approvalsContinuously updated, source-cited coverage. https://www.live-feeds.com/feed/fda-s-new-leadership-aims-to-overhaul-rare-disease-approvalshttps://www.live-feeds.com/feed/fda-s-new-leadership-aims-to-overhaul-rare-disease-approvals#u131824Sun, 18 Oct 2026 12:41:57 +0000The US Food and Drug Administration is launching a comprehensive top-to-bottom review of rare disease drug development and approvals under its new leadership. As part of this ongoing reset, the agency announced the Rare Disease Framework Initiative to develop a holistic and fit-for-purpose framework. This new approach shifts the regulatory focus toward greater consistency and predictability rather than traditional flexibility. The sweeping initiative also brings chemistry, manufacturing, and controls reviews into scope while evaluating the opportunities and limits of Bayesian methods in rare d